A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Description

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Conditions

Metastatic Castration-resistant Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Condition
Metastatic Castration-resistant Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Stanford Cancer Center, Palo Alto, California, United States, 94304

Sarasota

Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota, Florida, United States, 34232

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Durham

Duke Cancer Institute, Durham, North Carolina, United States, 27710

San Antonio

Local Institution - 0006, San Antonio, Texas, United States, 78229

San Antonio

NEXT Oncology, San Antonio, Texas, United States, 78229

Seattle

Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
  • * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
  • * Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
  • * Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
  • * Participant must not have history of brain metastases.
  • * Participant must not have impaired cardiac function or clinically significant cardiac disease.
  • * Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2029-01-16